Eighty-four clinical isolates of the family
Except for the pair of K. pneumoniae isolates recovered in center WA II (WA II isolates 8932 and 8933), all isolates were collected from different patients who were hospitalized in diverse types of wards, mostly in intensive care units (28 patients), neonatal wards (10 patients), and internal medicine wards (10 patients). Eleven isolates were cultured in centers WA I and WA II, which are hospitals that specialize in the treatment of patients with hematological and/or oncological disorders. The majority of the isolates (47 isolates; 56.0%) were identified in urine samples, followed by those recovered from bronchial exudates (7 isolates), blood (6 isolates), and infected postoperative wound swabs (5 isolates). Species identification was performed with the ATB ID32E test (bioMérieux, Charbonnieres-les-Bains, France), and the isolates were tested for ESBL production by the double-disk synergy (DDS) test (20) with disks containing cefotaxime, ceftazidime, and amoxicillin with clavulanate (Oxoid, Basingstoke, United Kingdom). The disks were placed 20 mm apart (from center to center); for selected isolates the test was repeated with the distance reduced to 15 mm.
Antimicrobial susceptibility testing. The MICs of various antibiotics were determined by the agar dilution method in accordance with National Committee for Clinical Laboratory Standards guidelines (27) . In all ␤-lactam-inhibitor combinations the constant concentrations of clavulanate and tazobactam were 2 and 4 g/ml, respectively. E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as reference strains.
Conjugative transfer of ␤-lactamase genes (mating). Bacterial conjugation was performed as described previously (17) with E. coli A15 R Ϫ recipient strains resistant to rifampin or nalidixic acid. Transconjugants were selected on MacConkey agar (bioMérieux) plates supplemented with cefotaxime (2 g/ml; Polfa) and rifampin (128 g/ml; Polfa) or nalidixic acid (64 g/ml; Sigma Chemical Company).
IEF of ␤-lactamases and bioassay for cephalosporin-hydrolyzing activities. Isoelectric focusing (IEF) of the ␤-lactamases was carried out with bacterial sonicates by the modified procedure described previously (5, 26) in a Mini IEF Cell (model 111; Bio-Rad, Hercules, Calif.). After IEF, the cefotaxime-and ceftazidime-hydrolyzing activities of particular ␤-lactamases were detected by the bioassay approach, as described by Bauernfeind et al. (5) . Each of the two cephalosporins was used at a concentration of 2 g/ml.
PCR detection of bla CTX-M , bla SHV , and bla TEM genes. Total DNAs of the isolates or their transconjugants were purified with a Genomic DNA Prep Plus kit (A & A Biotechnology, Gdańsk, Poland). The complete coding sequences of the bla CTX-M genes were amplified with primers P1C and P2D, and PCRs were run as reported previously (17) . Primers SHV-A and SHV-C (16, 30) were used for partial amplification of the genes encoding SHV ␤-lactamases, whereas the entire bla TEM genes were amplified with primers TEM-A and TEM-B (24) . PCR conditions were identical to those described previously (16, 30) .
Sequencing of bla CTX-M genes. The PCR products encompassing the complete coding regions of the bla CTX-M genes were sequenced (36) by using consecutive primers specific for the bla CTX-M-1 gene (6) in a DNA sequencer (ABI PRISM 310; Applied Biosystems, Foster City, Calif.). Sequencing of both DNA strands was performed with the following primers: P1C (5Ј-TTAATTCGTCTCTTCCA GA-3Ј), A (5Ј-GAAAAGTGAAAGCGAACCGA-3Ј), P1A (5Ј-GGCGATCCG CGTGATACCAC-3Ј), P2D (5Ј-CAGCGCTTTTGCCGTCTAAG-3Ј), P2A (5Ј-GTGGTATCACGCGGATCGCC-3Ј), and P2B (5Ј-CGCTGATTTAACAGAT TCGG-3Ј) (6) .
RAPD typing. The genomic DNAs of the isolates were used in the randomly amplified polymorphic DNA (RAPD) analysis with primers RAPD-7 and RAPD-1283 (34) . PCRs were run as described previously (16 (30) .
PFGE typing. Pulsed-field gel electrophoresis (PFGE) analysis was performed with a CHEF DRII PFGE system (Bio-Rad) by the procedure described by Struelens et al. (38) . Results were interpreted in accordance with the criteria proposed by Tenover et al. (39) . Three CTX-M-producing isolates identified in 1996 and 1997 in Praski Hospital in Warsaw, K. pneumoniae WA VII 10, E. coli WA VII 13, and C. freundii WA VII 21 (30) , were included in the study.
Plasmid DNA fingerprinting. Plasmid DNA was purified from bacterial cells by the alkaline lysis method (7) with a QIAGEN Plasmid Midi kit (QIAGEN, Hilden, Germany). For the fingerprinting analysis, plasmid DNA was digested with the PstI restriction enzyme (MBI Fermentas, Vilnius, Lithuania). Plasmids specific for the group of CTX-M-producing isolates from 1996 and 1997 in Praski Hospital in Warsaw (30) were included in the study; these plasmids were purified from K. pneumoniae WA VII 18, 179, E. coli WA VII 279, S. marcescens WA VII 12, and transconjugants of isolates E. coli WA VII 6 and WA VII 13 and S. marcescens WA VII 275 and WA VII 278.
RESULTS
Resistance phenotypes of isolates in DDS test. Seventythree isolates were identified as putative ESBL producers on the basis of positive results by the DDS test (20) . The remain- Table 2 . All the isolates were found to produce ␤-lactamases with a pI of 8.4; these were perpetually accompanied by enzymes with a pI of 5.4. Other ␤-lactamases of various pI values were also identified in some of the isolates, and these included enzymes with pIs of 8.2 and 6.0 that were expressed by 11 K. pneumoniae isolates. The most frequent were pI 8.2 ␤-lactamases observed in eight isolates from three hospitals (isolates SU 8406, SU 8815, SU 8912, SU 9148, SU 9161, and SU 972, SZ 2941, and WA V 7888), whereas enzymes with a pI of 6.0 were produced by three isolates from two other institutions (isolates CZ 9455, CZ 9459, and KR 3443). Almost all K. pneumoniae isolates expressed ␤-lactamases with a pI of 7.6, and some isolates of other species produced enzymes with pIs of Ϸ9.0 (multiple S. marcescens isolates), 8.0 (E. cloacae KA 3663), or 7.0 (C. freundii WA I 4185, WA I 4358, and WO 9105). The S. marcescens pI Ϸ9.0 ␤-lactamases were observed either as "strong" IEF bands (isolates CZ 9424, WA I 4172, and WA V 3033) or as relatively "weak" ones.
Resistance transfer and ␤-lactamase content of transconjugant strains. The results of the analyses of resistance transfer and the ␤-lactamase contents of the transconjugant strains are shown in Table 2 . Seventy-one isolates of all species identified produced transconjugants that were selected on the cefotaxime-containing medium. For the majority of isolates (56 
a pI values in boldface refer to ␤-lactamases that were found to hydrolyze only cefotaxime in the bioassay experiment, whereas pI values which are in boldface and underlined represent enzymes that hydrolyzed both cefotaxime and ceftazidime. Table 2 . In all transconjugants the pI 8.4 ␤-lactamase demonstrated cefotaxime-hydrolyzing activity but not ceftazidime-hydrolyzing activity under the conditions used in the assay, whereas the pI 8.2 enzyme (from the transconjugant of K. pneumoniae WA V 7888) and the pI 6.0 enzyme (from recombinants of K. pneumoniae CZ 9455 and CZ 9459) hydrolyzed the two compounds. The analysis performed with extracts from clinical isolates confirmed these observations in general; however, it has also assigned the activity against both cefotaxime and ceftazidime to some ␤-lactamases produced by DDS test-negative or problematic E. cloacae, C. freundii, and S. marcescens isolates. These were enzymes with pIs of Ϸ9.0 (only in S. marcescens isolates CZ 9424, WA I 4172, and WA V 3033), 8.4 (E. cloacae CZ 8320 and WA IV 838 and C. freundii SU 9050, WA V 3324 and WA V 3570), and 8.0 (E. cloacae KA 3663).
Detection of ESBL-encoding genes by PCR.
The results of the detection of ESBL-encoding genes by PCR are shown in Table 2 . All clinical isolates were tested for the presence of genes coding for the CTX-M family of ESBLs with primers that are specific for both the bla CTX-M-1 and the bla CTX-M-3 genes (6, 17) . PCR products of the expected size (approximately 1 kb) were obtained for all isolates. Detection of bla SHV genes was performed for all the K. pneumoniae isolates which produced, in addition, the pI 8.2 ␤-lactamase (isolates SU 8406, SU 8815, SU 8912, SU 9148, SU 9161, and SU 972, SZ 2941, and WA V 7888) and for the only transconjugant that did so (a transconjugant of K. pneumoniae WA V 7888). The primers used in this analysis are specific for genes encoding SHV ␤-lactamases, which possess ESBL-type G238S and E240K substitutions (30) . PCR products of the expected size of about 200 bp were obtained for the strains analyzed. Total DNAs of the transconjugants expressing the pI 6.0 ESBL (K. pneumoniae CZ 9455 and CZ 9459) were used for the detection of bla TEM genes, and amplicons of the expected size of about 1 kb were observed.
Sequencing of bla CTX-M genes. The complete nucleotide sequence of the bla CTX-M gene coding region was determined for 27 isolates. These isolates represented different species (12 K. pneumoniae isolates, 1 K. oxytoca isolate, 9 E. coli isolates, 2 E. cloacae isolates, 2 C. freundii isolates, and 1 M. morganii isolate) and different centers (all centers except KA and WA IV). In addition, the MICs for the transconjugants varied within the range of values determined for recombinant strains (see below). The results are listed in Table 2 . All isolates analyzed were found to contain bla CTX-M-3 genes with coding regions with identical nucleotide sequences (17) .
Typing by RAPD analysis and PFGE. All clinical isolates except for the single M. morganii strain were typed by RAPD analysis in conjunction with 15 CTX-M-producing isolates recovered in 1996 and 1997 in Praski Hospital in Warsaw (center WA VII), in which the CTX-M-3 ESBL was originally identified (17) . These isolates represented almost all RAPD types of CTX-M producers that had been discerned at the time in the institution (30) . In general, a high degree of diversity of RAPD patterns was observed among isolates of all species identified. Including the isolates from Praski Hospital, 19 RAPD types were identified among 40 K. pneumoniae isolates, 17 types were identified among 21 E. coli isolates, 8 types were identified among 10 E. cloacae isolates, and 6 types were identified among 12 C. freundii isolates. The analysis discriminated all 4 K. oxytoca isolates and 11 S. marcescens isolates. At a singlecenter level, only four clusters of more than two indistinguishable isolates were revealed; and these were clusters of K. pneumoniae isolates collected in four hospitals (BB, five isolates; CZ, five isolates; SU, seven isolates; SZ, three isolates). Additionally, 10 pairs of isolates of different species were characterized by identical RAPD patterns within particular centers.
Several cases of the identity of RAPD patterns were found among isolates recovered in different hospitals (Table 3) . This was observed for two pairs of K. pneumoniae isolates, one pair of E. coli isolates, and two clusters of four and three C. freundii isolates, respectively. All these isolates were subjected to PFGE typing, and the results of the analysis, shown in 
a "WA VII" is the designation for Praski Hospital in Warsaw, and the isolates collected in this center in 1996 and 1997 (30) were used only in the comparative typing in this work.
b RAPD types were designated by letters independently for each group of isolates by species.
PFGE patterns (PFGE type ␣) and were found to be possibly related. The possible relatedness of three C. freundii isolates from centers WA I and WO (isolates WA I 4185, WA I 4358, and WO 9105; PFGE type ␤) was also confirmed.
Plasmid fingerprinting. Plasmid DNAs specific for 43 clinical isolates of different species, centers, and RAPD types were subjected to a fingerprinting analysis. Plasmids representing all fingerprints identified in 1996 and 1997 in CTX-M-producing isolates from Praski Hospital in Warsaw (designated A1 to A7 and B) (30) were included in the study. In the majority of cases plasmid DNA was purified from transconjugant strains (only if these were available). All the isolates contained high-molecular-weight plasmids, which in many cases were accompanied by various smaller molecules. Altogether, 31 different fingerprints were distinguished among the isolates; however, large plasmids of 41 isolates revealed highly similar restriction patterns that were either identical (variant A1) or similar (variants A8 to A35) to those previously observed in the isolates from Praski Hospital (variants A1 to A7). The only A-type plasmid variant which was present in multiple isolates was plasmid A1, found alone in 12 isolates of various species that were recovered in nine hospitals (BB, CZ, KA, SU, WA I, WA IV, WA V, WO, and WR). Two single E. coli isolates from two centers (isolates SU 8350 and BB 1775) contained large plasmids with remarkably different PstI fingerprints (patterns C and D, respectively).
Antimicrobial susceptibilities of clinical isolates. Table 4 shows the ranges of MICs grouped with regard to specific groups of isolates. The MICs of ampicillin and imipenem are not given in Table 4 as they were the same for all isolates (ampicillin MICs, Ͼ512 g/ml; imipenem MICs, 0.125 to 1 g/ml). The MIC patterns for 60 isolates of all species identified were characteristic for the CTX-M family of ESBL producers (4, 5, 30) . The cefotaxime MICs for these isolates were higher by 3 to 8 dilutions than those of ceftazidime, and clavulanate reduced cefotaxime MICs by at least 5 dilutions and usually 8 or more dilutions. Nevertheless, a high degree of quantitative diversity of MICs was observed among these isolates, especially K. pneumoniae, and this is well illustrated by the MICs of cefotaxime (MICs, 2 to 512 g/ml), ceftazidime (MICs, 0.25 to 16 g/ml), or piperacillin with tazobactam (MICs, 1 to 256 g/ml). Besides the cefoxitin resistance of the E. cloacae, C. freundii, and S. marcescens isolates, resistance to this drug appeared in sporadic isolates of this group.
The susceptibility patterns of the 24 remaining isolates differed from those typical of CTX-M producers, and they could be classified into four groups, three of which included only K. pneumoniae. The first was formed by eight K. pneumoniae isolates (isolates SU 8406, SU 8815, SU 8912, SU 9148, SU 9161, SU 972, SZ 2941, and WA V 7888), which, apart from CTX-M-3, also produced SHV ESBLs. The ceftazidime MICs for these isolates (64 to 128 g/ml) were higher than the cefotaxime MICs (16 to 64 g/ml). The ceftazidime MICs for the three K. pneumoniae isolates (isolates CZ 9455, CZ 9459, and KR 3443) that coexpressed the CTX-M-3 and TEM ESBLs were also elevated (32 to 64 g/ml), although the cefotaxime MICs for these three isolates (128 to 256 g/ml) remained higher. The third specific fraction of K. pneumoniae isolates consisted of four isolates from three centers (isolates SZ 3733, SZ 3734, WA II 8933, and WA IV 9172); two of these isolates (isolates WA II 8933 and WA IV 9172) were negative by the DDS test. In general, the ␤-lactam MICs, including the MICs of inhibitor combinations, for these isolates were very high (e.g., cefotaxime MICs, 512 to Ͼ512 g/ml; ceftazidime MICs, 32 to 64 g/ml; cefoxitin MICs, 32 to 128 g/ml, cefotaxime plus clavulanate MICs, 128 to 512 g/ml).
The last group consisted of nine isolates (E. cloacae CZ 8320, KA 3663, and WA IV 838; C. freundii SU 9050, WA V 3324, and WA V 3570; and S. marcescens CZ 9424, WA I 4172, and WA V 3033) that produced negative or unclear results by the DDS test. They were characterized by high MICs of cefotaxime (256 to 512 g/ml), ceftazidime (16 to 128 g/ml), and inhibitor combinations (e.g., cefotaxime plus clavulanate MICs, 32 to 256 g/ml).
Antimicrobial susceptibilities of transconjugants. Results of the analysis of the antimicrobial susceptibilities of the transconjugants are shown in Table 4 . Data for ampicillin and imipenem are not included as they were the same for all transconjugants (ampicillin MICs, 512 to Ͼ512 g/ml; imipenem MICs, 0.125 to 0.25 g/ml). For most of the transconjugants that expressed only CTX-M-3 and the pI 5.4 ␤-lactamase, the MICs were much lower than those for clinical isolates, but the MICs for the strains were still markedly diverse, with MIC patterns that are characteristic for CTX-M producer strains (4, 5, 30) . Cefotaxime MICs (4 to 32 g/ml) were 3 or more dilutions higher than those of ceftazidime (0.25 to 2 g/ml), and ␤-lactamase inhibitors efficiently reduced the MICs of the ␤-lactams (e.g., cefotaxime plus clavulanate MICs, Յ0.03 to 0.06 g/ml). Strongly elevated MICs characterized recombinants of two of the four K. pneumoniae isolates for which the MICs of ␤-lactams and ␤-lactam plus inhibitor combinations were particularly high (K. pneumoniae SZ 3733 and SZ 3734). The MICs of oxyimino-␤-lactams for these transconjugants were higher (e.g., cefotaxime MICs, 128 g/ml; ceftazidime MICs, 8 g/ml); however, the MICs of inhibitor combinations for these transconjugants were not significantly increased.
The only transconjugant which coexpressed CTX-M-3 and the SHV ESBL (a transconjugant of K. pneumoniae WA V 7888) was characterized by similar cefotaxime and ceftazidime MICs (cefotaxime MIC, 16 g/ml; ceftazidime MIC, 8 g/ml), as was the case for the recombinants of two K. pneumoniae isolates (isolates CZ 9455 and CZ 9459) that produced only TEM ESBLs (cefotaxime MICs, 4 to 8 g/ml; ceftazidime MICs, 4 g/ml).
DISCUSSION
The 1998 survey of the prevalence of different ESBL types among ESBL producers in seven hospitals in Poland has suggested an important role of CTX-M enzymes on a wider scale (M. Gniadkowski, A. Baraniak, J. Fiett, and W. Hryniewicz, unpublished results). CTX-M ␤-lactamases (identified by IEF, bioassay, and PCR) were found in 18.8% of 96 isolates collected within a 4-month period, and the isolates were recovered in six different centers. This frequency was below that of SHV-type ESBLs (60.4%); however, it was comparable to the prevalence of TEM enzymes (20.8%). The study reported here was carried out both with the isolates identified during the survey and with new isolates, recovered later in nine other hospitals, which were suspected to be CTX-M producers on the basis of preliminary phenotype observations and IEF analysis.
Eighty-four clinical isolates of the family Enterobacteriaceae collected from 15 medical institutions in Poland were found to produce a CTX-M ␤-lactamase with a pI of 8.4 that revealed the characteristic cefotaxime-hydrolyzing activity but not ceftazidime-hydrolyzing activity in vitro. The ␤-lactamase was always expressed together with a pI 5.4 ␤-lactamase, and genes coding for the two types of enzymes were located on the same plasmids, which in the majority of isolates had conjugative functions. DNA sequencing, performed for 27 isolates, revealed that they all expressed CTX-M-3. The CTX-M-3 ␤-lactamase was originally identified in three C. freundii isolates in mid-1996 in Praski Hospital in Warsaw (17) , and the enzyme was probably spread in that institution in 1996 and 1997 (30) . In 1998 a CTX-M-3-producing E. cloacae strain was recovered in a hospital in Versailles, France (13) , and then, in 1999, E. coli strains expressing the same enzyme were found in southern Taiwan (42) . CTX-M-3 is closely related to the CTX-M-1/ MEN-1 enzyme identified in Germany (5; A. Bauernfeind,, H. Grimm, I. Stemplinger, S. Ernst, and R. Jungwirth, Final Program Abstr. 19th Int. Congr. Chemother., Can. J. Infect. Dis. 6(Suppl. C):470C, abstr. 4210, 1995) and France (in an isolate from an Italian patient) (3), the CTX-M-10 enzyme reported in Spain (29) , the CTX-M-12 enzyme from Kenya (21) , and the CTX-M-11 enzyme from China and the CTX-M-3-like enzyme from Japan (GenBank accession numbers AY005110 and AY013478, respectively) (www.lahey.org/studies/webt.htm). These ␤-lactamases form a distinct branch within the evolutionary tree of CTX-M ESBLs (8; www.lahey.org/studies/webt .htm).
Isolation of CTX-M-3-producing strains of the family Enterobacteriaceae in 15 health care centers in 10 different cities of Poland is indicative of the spread of these organisms in the whole country. Six of the centers are located in Warsaw, and this means that, together with Praski Hospital, there are seven separate institutions in the city in which CTX-M-3 has been identified to date. Such a countrywide dissemination of CTX-M producers seems to be very rare and may be compared only to the situation in Argentina, where CTX-M-2 (4, 6) has been reported to be the most frequently occurring ESBL type (M. F. Galas, M. J. Rapoport, F. G. Pasteran, R. G. Melano, A. E. Petroni, P. G. Ceriana, WHONET Group, and A. Rossi, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1474, p. 165, 1999). The typing and plasmid fingerprinting analyses of the isolates have brought important insight into the spread of CTX-M-3 in Poland. The high degree of diversity of the RAPD types of isolates of all species suggested that the clonal dissemination of producer strains, even if important in some of the centers, did not play the predominant role in the overall situation. On the other hand, the location of the bla CTX-M-3 genes within large conjugative plasmids with identical or similar fingerprints (A-type plasmids) in the majority of the isolates indicated that horizontal plasmid transfer was the main mechanism of CTX-M-3 spread. The observed heterogeneity of A-type plasmids probably reflects the ongoing diversification of the molecules, and it is likely that the A1 variant, which was carried by multiple isolates from nine hospitals, was the ancestor of the whole family. It is noteworthy, however, that the bla CTX-M-3 genes may also reside in plasmids with clearly distinct fingerprints, which were found in single E. coli isolates from centers BB and SU (plasmids C and D, respectively) and from Praski Hospital in 1996 and 1997 (plasmid B) (30) .
The spread of a single type of transferable plasmids within bacterial populations within numerous, geographically separated hospitals has raised the question of the origins of these plasmids in particular centers. The most likely hypothesis is that they were transmitted from one center to another with bacterial strains by means of patient transfer, which is a common practice in Poland and which occurs between all types of hospitals. Recognition of all strains that could constitute a "network of epidemiological links" involving all the centers in the study would be difficult in practice; however, the identification of related organisms in two or more hospitals has supported the hypothesis of strain transmission. The majority of related isolates were collected in three Warsaw centers including Praski Hospital, and all these were linked to each other by a single clone of C. freundii, designated PFGE type ␣. This epidemic strain was originally identified as clonally spread in 1996 and in 1996 and 1997 in Praski Hospital (17, 30) , and in the present work it was also found in centers WA I and WA V. Other related isolates were observed in Praski Hospital and centers WA I (K. pneumoniae) and SZ (E. coli), in hospitals WA V and SZ (K. pneumoniae), and in centers WA I and WO (C. freundii). Although fragmentary, these data suggest that the transmission of several CTX-M-3-producing strains preceded the dissemination of plasmids with the bla CTX-M-3 gene in Polish hospitals.
Antimicrobial susceptibility testing has revealed the high degree of diversity of the resistance phenotypes of CTX-M-3-producing strains, which to some extent was also demonstrated by the DDS test. This diversity was mostly manifested in the overall level of ␤-lactam resistance, the ratio of the rate of resistance to cefotaxime and the rate of resistance to ceftazidime, and the potencies of ␤-lactamase inhibitors in reducing ␤-lactam MICs. Several factors, including both species-and strain-specific factors, may explain these observations. One of these was the production of an additional ESBL. Altogether, 11 K. pneumoniae isolates from five centers also expressed, apart from CTX-M-3, cefotaxime-and ceftazidime-hydrolyzing ␤-lactamases of the SHV (pI 8.2) or the TEM (pI 6.0) family. These enzymes were probably responsible for the elevated MICs of ceftazidime (compared to those of cefotaxime) which characterized the isolates. The presence of two different ESBL types in a single clinical isolate seems to be rare, although such combinations have already been reported, for example, in France and Argentina (37; Galas et al., 39th ICAAC; F. Pasteran and M. Galas, Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1607, p. 153, 2000). Some other ␤-lactamases that were observed as separate IEF bands in protein extracts of the clinical isolates, such as those with pIs of 5.4 (probably TEM-1), 7.6 (probably species-specific K. pneumoniae enzymes), or 7.0, did not show cefotaxime-or ceftazidime-hydrolyzing activity in the bioassay under the conditions used. Most likely, these enzymes did not affect significantly the oxyimino-␤-lactam resistance of the isolates; however, in general, they must have contributed to their ␤-lactam resistance phenotypes.
The other group of isolates with complex phenotypes consisted of nine isolates of E. cloacae, C. freundii, and S. marcescens, all of which had negative or unclear results by the DDS test. These species are known to frequently segregate mutants with the derepressed expression of specific class C (AmpC) cephalosporinases (22) . The phenotypes of such mutants manifest in high MICs of the majority of oxyimino-␤-lactams and inhibitor combinations, which were observed for the nine isolates. Their protein extracts revealed both cefotaxime-and ceftazidime-hydrolyzing activities within ␤-lactamase IEF bands with pIs of Ϸ9.0, 8.4, or 8.0, which is in accordance with the published data on AmpC enzymes (12) . The E. cloacae and C. freundii isolates, in which the cefotaxime-and ceftazidimehydrolyzing activities were assigned to the pI 8.4 ␤-lactamase band, produced transconjugants with only the cefotaxime-hydrolyzing pI 8.4 ␤-lactamase. This indicated that their AmpC enzymes probably comigrated with CTX-M-3 in the IEF analysis. Such ESBL-producing AmpC derepressed mutants have been reported in several papers to date (2, 28) . What is noteworthy is that of the remaining isolates of the AmpC producer species, the putative AmpC ␤-lactamases were observed as separate IEF bands (weak pI Ϸ9.0 bands) only in S. marcescens isolates. Their presence, however, was clear, as indicated by increased cefoxitin MICs for all these isolates (probably due to the AmpC induction effect), and so they must have contributed to the isolates' resistance levels, too. It is possible that at least in the majority of these isolates the AmpC IEF bands were masked by CTX-M-3, as was the case for the E. cloacae and C. freundii AmpC-derepressed mutant isolates.
The high degree of quantitative diversity of the MICs observed for the isolates and transconjugants that produced CTX-M-3 as the only oxyiminocephalosporin-hydrolyzing enzyme suggested that the CTX-M-3 expression level and/or the permeability for ␤-lactam antibiotics could also vary in the isolates. This was especially explicit in the case of four distinguished highly resistant K. pneumoniae isolates from centers SZ, WA II, and WA IV. Among the transconjugants, the ␤-lactam MICs for recombinants of K. pneumoniae SZ 3733 and SZ 3734 were particularly high, which indicated the possibility of higher-level CTX-M-3 expression. However, the clearly elevated MICs of cefoxitin and the inhibitor combinations that were shown for the isolates themselves indicated that another mechanism, probably a permeability-based resistance mechanism, could also exist in these isolates. The only two DDS test-negative K. pneumoniae strains, strains WA II 8933 and WA IV 9172, were characterized by an even higher level of resistance to ␤-lactams (including cefoxitin), and ␤-lactamase inhibitors had almost no effect against the strains. Since the MICs for the transconjugant of isolate WA II 8933 did not reveal any significant increases, it is likely that these two isolates had strongly decreased permeabilities for ␤-lactam antibiotics. Numerous reports over recent years have documented the decreased permeabilities for ␤-lactams in strains of the family Enterobacteriaceae, which is usually due to mutational changes in genes coding for outer membrane porins. This mechanism has been found to be sufficient to significantly influence the level of bacterial resistance to ␤-lactams and ␤-lactam plus inhibitor combinations, especially when it coexists with various ␤-lactamases, including ESBLs (25, 31, 41) .
The data presented in this work document the very complex epidemiology of the CTX-M-3 ␤-lactamase in Poland, which is one of the major ESBL types in the country. Such a widespread nature of CTX-M producers seems to be unique in Europe, and in the world it may be compared only with the situation in Argentina. The spread of this ␤-lactamase may mainly be attributed to the very efficient dissemination of plasmids with the bla CTX-M-3 gene in different hospitals (but to some extent it may also be attributed to clonal spread) which followed the noncontrolled transmission of producer strains among them. CTX-M-3-expressing strains constantly evolve in hospitals, acquiring other mechanisms of resistance to ␤-lactams, which is most likely driven by the high-level use of newer ␤-lactam antibiotics.
